Advertisement

Drugs & Aging

, Volume 8, Issue 4, pp 245–274 | Cite as

Cognition Enhancers in Age-Related Cognitive Decline

Review Article Drug Therapy

Summary

A review of recently published studies on the effect of cognition enhancers in non-demented human study participants is presented. The heterogeneity of the therapeutic target, age-associated cognitive decline, can be improved by separately treating groups in whom age-extrinsic factors may underlie cognitive pathology. Standardisation of cognitive assessments is necessary, since many different tests are applied to answer the same question. Modelling cognitive dysfunction, either by pharmacological or nonpharmacological means, in humans is highly recommended since it allows hypotheses to be tested in a clearly operationalised way. Predictive validity of the currently applied models for the clinical situation remains a problem, however. The scopolamine (hyoscine) model has, to a reasonable extent, predictive validity for the cholinergic agents.

The results of 67 single-dose studies and 30 multiple-dose studies are summarised. All single-dose studies and 14 multiple-dose studies were carried out in young or elderly human volunteers. In 45 of 81 volunteer studies, models of cognitive dysfunction were employed. The scopolamine model was the most used (n = 21); the other studies induced cognitive dysfunction by means of benzodiazepines (8), hypoxia (7), alcohol (5) and sleep-deprivation (4). The remaining 16 multiple-dose studies were clinical trials of a duration varying between 2 weeks and 1 year (average duration was 14 weeks). In these trials, the effects of cognition enhancers were assessed in elderly people in whom impairment of memory, psychomotor performance or cognitive function was determined. These included age-associated memory impairment (AAMI) and age-associated cognitive decline (AACD).

There were many studies in which the cognition enhancing properties of substances in humans were reliably demonstrated. The cognition enhancing properties of substances that are widely used, such as caffeine, nicotine and vitamins, may already be active against AACD. New developments such as serotonin (5-hydroxytryptamine3; 5-HT3) antagonists and N-methyl-D-aspartate (NMDA) antagonists have provided marginal and disappointing results in AAMI. There is no cognition enhancer that has reliably and repeatedly been demonstrated to be efficacious for the treatment of AACD. However, this situation may change as the selectivity, specificity and adverse effect profiles of substances that are being developed for the treatment of AD may be expected to be improved in the future.

Keywords

Nicotine Caffeine Adis International Limited Scopolamine Flumazenil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Charness N, editor. Aging and human performance. Waterloo, Canada: John Wiley & Sons, 1985Google Scholar
  2. 2.
    Birren JE, Warner Schaie K, editors. Handbook of the psychology of aging. 3rd ed. New York: Van Nostrand Reinhold Company, 1990Google Scholar
  3. 3.
    LaRue A. Aging and Neuropsychological Assessment. New York: Plenum Press, 1992Google Scholar
  4. 4.
    Jolles J, Verhey FRJ, Riedel WJ, et al. Cognitive impairment in elderly people: predisposing factors and implications for experimental drug studies. Drugs Aging 1995; 7: 459–79PubMedGoogle Scholar
  5. 5.
    Masur DM, Sliwinski M, Lipton RB, et al. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994; 44: 1427–32PubMedGoogle Scholar
  6. 6.
    McEntee WJ, Crook TH. Age-associated memory impairment: a role for catecholamines. Neurology 1990; 40: 526–30PubMedGoogle Scholar
  7. 7.
    Pepeu G. Memory disorders: novel treatments, clinical perspective. Life Sci 1994; 55: 2189–94PubMedGoogle Scholar
  8. 8.
    O’Brien JT, Levy R. Age associated memory impairment. BMJ 1992; 304: 5–6PubMedGoogle Scholar
  9. 9.
    Ban TA. Psychopharmacology and succesful cerebral aging. Prog Neuropsych Biol Psychiatry 1994; 19: 1–9Google Scholar
  10. 10.
    Michel B, Sambuc R, Scotto JC. French recommendations for clinical drug trials in cognitive disorders of the elderly. Int J Geriatr Psychiatry 1994; 9: 823–8Google Scholar
  11. 11.
    Frostl W, Maitre L. The families of cognition enhancers. Pharmacopsychiatry 1989; 2: 54–100Google Scholar
  12. 12.
    Sarter M, Hagan J, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I. Psychopharmacology 1992; 107: 144–59PubMedGoogle Scholar
  13. 13.
    Cacabelos R, Nordberg A, Caamano J, et al. Molecular strategies for the first generations of antidementia drugs (1). Tacrine and related compounds. Drugs Today 1994; 30: 295–337Google Scholar
  14. 14.
    Porsolt RD. Strategies in psychopharmacology: cognition enhancers — from animals to man: concluding remarks. Pharmacopsychiatry 1990; 23: 99–100Google Scholar
  15. 15.
    Schwartz G, Bisserbe JC, Bradford D, et al. Late clinical testing of cognition enhancers: demonstration of efficacy. Pharmacopsychiatry 1990; 2: 60–2Google Scholar
  16. 16.
    Müller WE, Pedigo NW. Brain aging: a risk factor of neurodegenerative disorders and a target for therapeutic intervention. Life Sci 1994; 55: 1975–6PubMedGoogle Scholar
  17. 17.
    Caine ED. Should aging-associated cognitive decline be included in DSM-IV? J Neuropsychiatry Clin Neurosci 1993; 5: 1–5PubMedGoogle Scholar
  18. 18.
    Giurgea CE. The ‘nootropic’ approach to the pharmacology of the integrative activity of the brain. Conditional Reflex 1973; 8: 108–15PubMedGoogle Scholar
  19. 19.
    Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev 1994; 19: 180–222PubMedGoogle Scholar
  20. 20.
    Sarter M, Hagan J, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II. Psychopharmacology 1992; 107: 461–73PubMedGoogle Scholar
  21. 21.
    Giacobini E, Becker R, editor. Alzheimer’s disease: therapeutic strategies. Basel: Birkhäuser Verlag AG, 1994Google Scholar
  22. 22.
    Kral VA. Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962; 86: 257–60PubMedGoogle Scholar
  23. 23.
    Crook T, Bartus RT, Ferris SH, et al. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change. Report of a National Institute of Mental Health work group. Dev Neuropsychol 1986; 2: 261–76Google Scholar
  24. 24.
    Blackford RC, LaRue A. Criteria for diagnosing age-associated memory impairment: proposed improvements from the field. Dev Neuropsychol 1989; 5: 295–306Google Scholar
  25. 25.
    Bamford KA, Caine ED. Does ‘benign senescent forgetfulness’ exist? Clin Geriatr Med 1988; 4: 897–916PubMedGoogle Scholar
  26. 26.
    Tritsmans L, Clincke G, Peelmans B. Does AAMI constitute a real disease entity? A placebo-controlled double-blind study with sabeluzole (R58 735) in a patient population with real memory problems. Drug Dev Res 1990; 20: 473–82Google Scholar
  27. 27.
    Rosen TJ. ‘Age-associated memory impairment’: a critique. Special issue: cognitive gerontology. Eur J Cogn Psychol 1990; 2: 275–87Google Scholar
  28. 28.
    Smith G, Ivnik RJ, Petersen RC, et al. Age-associated memory impairment diagnosis: problems of reliability and concerns for terminology. Psychol Aging 1991; 6: 551–8PubMedGoogle Scholar
  29. 29.
    Abate G, Angeleri F, Bartorelli L, et al. Epidemiologic study on the effectiveness and safety of dihydroergocristine in impaired memory and behavioral functions in aged humans. Arzneimittelforschung 1992; 42: 1417–21PubMedGoogle Scholar
  30. 30.
    Clincke GH, Tritsmans L, Peelmans B. Long-term follow-up treatment with sabeluzole in elderly patients with pronounced memory problems of unknown origin. Drug Dev Res 1991; 23: 301–5Google Scholar
  31. 31.
    Schmidt U, Brendemuhl D, Engels K, et al. Piracetam in elderly motorists. Pharmacopsychiatry 1991; 24: 121–6PubMedGoogle Scholar
  32. 32.
    Riedel WJ. Cognition enhancing drugs, cholinergic function and age-related decline. Maastricht: Neuropsych Publishers, 1995Google Scholar
  33. 33.
    Hijman R, Jolies J, Verhoeven WMA, et al. Desglycinamide-(Arg(8))-vasopressin in five trials with memory-disturbed patients. Hum Psychopharmacol 1992; 7: 7–23Google Scholar
  34. 34.
    Marini G, Caratti C, Peluffo F. Placebo-controlled double-blind study of pramiracetam (CI-879) in the treatment of elderly subjects with memory impairment. Adv Ther 1992; 9: 136–46Google Scholar
  35. 35.
    Fioravanti M, Bergamasco B, Bocola V, et al. A multicentre, double-blind, controlled study of piracetam vs placebo in geriatric patients with nonvascular mild-moderate impairment in cognition. New Trends Clin Neuropharmacol 1991; V: 27–34Google Scholar
  36. 36.
    Rai GS, Shovlin C, Wesnes KA. A double-blind, placebo controlled study of Ginkgo biloba extract (‘tanakan’) in elderly outpatients with mild to moderate memory impairment. Curr Med Res Opin 1991; 12: 350–5PubMedGoogle Scholar
  37. 37.
    Gamzu ER, Birkhimer LJ, Hoover T, et al. Early human trials in the assessment of cognition activators. Pharmacopsychiatry 1990; 2: 44–8Google Scholar
  38. 38.
    Hall ST, Puech A, Schaffler K, et al. Early clinical testing of cognition enhancers: prediction of efficacy. Pharmacopsychiatry 1990; 2: 57–8Google Scholar
  39. 39.
    Porsolt RD. Strategies in psychopharmacology: cognition enhancers — from animals to man [preface]. Pharmacopsychiatry 1990; 23: 29–30Google Scholar
  40. 40.
    Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–17PubMedGoogle Scholar
  41. 41.
    Bartus RT, Dean RL, Pontecorvo MJ, et al. The cholinergic hypothesis: a historical overview, current perspective, and future directions. Ann NY Acad Sci 1985; 444: 332–58PubMedGoogle Scholar
  42. 42.
    Drachman D, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974; 30: 113–21PubMedGoogle Scholar
  43. 43.
    Drachman D, Sahakian B. The effects of cholinergic agents on human learning and memory. In: Bareau A, Growdon J, Wurtman R, editors. Nutrition and the brain. New York: Raven Press, 1979: 351–66Google Scholar
  44. 44.
    Kopelman MD. The cholinergic neurotransmitter system in human memory and dementia: a review. Q J Exp Psychol A 1986; 38: 535–73PubMedGoogle Scholar
  45. 45.
    Kopelman MD, Corn TH. Cholinergic ‘blockade’ as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. Brain 1988; 111: 1079–110PubMedGoogle Scholar
  46. 46.
    Molchan SE, Martinez RA, Hill JL, et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev 1992; 17: 215–26PubMedGoogle Scholar
  47. 47.
    Wesnes K, Warburton DM. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 1984; 82: 147–50PubMedGoogle Scholar
  48. 48.
    Wesnes K, Revell A. The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology 1984; 84: 5–11PubMedGoogle Scholar
  49. 49.
    Wesnes K, Simpson PM, Kidd A. The use of a scopolamine model to study the nootropic effects of tenilsetam (CAS 997) in man. Med Sci Res Psychol Psychiatry 1987; 15: 1063–4Google Scholar
  50. 50.
    Preston GC, Ward C, Lines CR, et al. Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine. Psychopharmacology 1989; 98: 487–94PubMedGoogle Scholar
  51. 51.
    Nuotto E. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man. Eur J Clin Pharmacol 1983; 24: 603–9PubMedGoogle Scholar
  52. 52.
    Schmedtje JJ, Oman CM, Letz R, et al. Effects of scopolamine and dextroamphetamine on human performance. Aviat Space Environ Med 1988; 59: 407–10PubMedGoogle Scholar
  53. 53.
    Meador KJ, Loring DW, Lee GP, et al. In vivo probe of central cholinergic systems. J Gerontol 1988; 43: M158–62PubMedGoogle Scholar
  54. 54.
    Kennedy RS, Odenheimer RC, Baltzley DR, et al. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests. Aviat Space Environ Med 1990; 61: 615–21PubMedGoogle Scholar
  55. 55.
    Lister RG. The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 1985; 9: 87–94PubMedGoogle Scholar
  56. 56.
    Sarter M, Stephens DN. Beta-carbolines as tools in memory research: animal data and speculations. Psychopharmacol Ser 1988; 6: 230–45PubMedGoogle Scholar
  57. 57.
    Sarter M, Schneider HH, Stephens DN. Treatment strategies for senile dementia: antagonist β-carbolines. Trends Neurosci 1988; 11: 13–7PubMedGoogle Scholar
  58. 58.
    Lister RG. The effects of benzodiazepines and 5-HT1a agonists on learning and memory. In: Rodgers RJ, Cooper SJ, editors. 5-HT1a agonists, 5-HT3 antagonists and benzodiazepines. Chichester: Wiley, 1991: 267–80Google Scholar
  59. 59.
    Bahrke MS, Shukitt HB. Effects of altitude on mood, behaviour and cognitive functioning: a review. Sports Med 1993; 16: 97–125PubMedGoogle Scholar
  60. 60.
    Kraaier V, Van Huffelen AC, Wieneke GH. The hyperventilation-induced ischaemia model in human neuropharmacology: neurophysiological and psychometric studies of aniracetam and 3-OH aniracetam. Eur J Clin Pharmacol 1989; 36: 605–11PubMedGoogle Scholar
  61. 61.
    Saletu B, Grünberger J. The hypoxia model in human psychopharmacology: neuropsychological and psychometric studies with aniracetam. Hum Neurobiol 1984; 3: 171–81PubMedGoogle Scholar
  62. 62.
    Weinachter SN, Blavet N, O’Donnell RA, et al. Models of hypoxia and cerebral ischemia. Pharmacopsychiatry 1990; 2: 94–7Google Scholar
  63. 63.
    Hindmarch I, Kerr JS, Sherwood N. The effects of alcohol and other drugs on psychomotor performance and cognitive function. Alcohol Alcohol 1991; 26: 71–9PubMedGoogle Scholar
  64. 64.
    Nilsson LG, Backman L, Karlsson T. Priming and cued recall in elderly, alcohol intoxicated and sleep deprived subjects: a case of functionally similar memory deficits. Psychol Med 1989; 19: 423–33PubMedGoogle Scholar
  65. 65.
    Clausen TG, Wolff J, Carl P, et al. The effect of the benzodiazepine antagonist, flumazenil, on psychometric performance in acute ethanol intoxication in man. Eur J Clin Pharmacol 1990; 38: 233–6PubMedGoogle Scholar
  66. 66.
    Collins WE, Mertens HW. Age, alcohol, and simulated altitude: effects on performance and breathalyzer scores. Aviat Space Environ Med 1988; 59: 1026–33PubMedGoogle Scholar
  67. 67.
    Sanders AF. Towards a model of stress and human performance. Acta Psychol (Amst) 1983; 53: 61–97Google Scholar
  68. 68.
    McCann UD, Penetar DM, Shaham Y, et al. Sleep deprivation and impaired cognition. Possible role of brain catecholamines. Biol Psychiatry 1992; 31: 1082–97PubMedGoogle Scholar
  69. 69.
    Hunt E. What do we need to know about aging? In: Cerella J, Rybash J, Hoyer W, et al., editors. Adult information processing: limits on loss. San Diego: Academic Press Inc, 1993: 587–98Google Scholar
  70. 70.
    Hobus P. Expertise van huisartsen. Praktijkervaring, kennis en diagnostische hypothesevorming. Maastricht: Rijksuniversiteit Limburg, 1994Google Scholar
  71. 71.
    Hijman R. Desglycinamide-(Arg(8))-vasopressin in patients with memory disturbances. Utrecht: University Press, 1992Google Scholar
  72. 72.
    Brand N, Jolles J. Learning and retrieval rate of words presented auditorily and visually. J Gen Psychol 1985; 112: 201–10PubMedGoogle Scholar
  73. 73.
    Rey A. L’examen psychologique dans les cas d’encéphalopathie traumatique. Paris: Presses Universitaires de France, 1964Google Scholar
  74. 74.
    Buschke H. Selective reminding for analysis of memory and learning. J Verbal Learning Verbal Behav 1973; 12: 543–50Google Scholar
  75. 75.
    Sternberg S. Memory scanning: mental processes revealed by reaction time experiments. Am Sci 1969; 57: 421–57PubMedGoogle Scholar
  76. 76.
    Verhaeghen P, Marcoen A, Goossens L. Facts and fiction about memory aging: a quantitative integration of research findings. J Gerontol 1993; 48: P157–71PubMedGoogle Scholar
  77. 77.
    Brand N, Jolies J. Information processing in depression and anxiety. Psychol Med 1987; 17: 145–53PubMedGoogle Scholar
  78. 78.
    Saletu B, Anderer P, Kinsperger K, et al. Topographic brain mapping of EEG in neuropsychopharmacology — part II. Clinical applications (pharmaco EEG imaging). Methods Find Exp Clin Pharmacol 1987; 9: 385–408PubMedGoogle Scholar
  79. 79.
    Michel CM, Lehmann D. Single doses of piracetam affect 42-channel event-related potential microstate maps in a cognitive paradigm. Neuropsychobiology 1993; 28: 212–21PubMedGoogle Scholar
  80. 80.
    Wesnes KA, Anand R, Simpson PM, et al. The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. J Psychopharmacol 1990; 4: 219–32PubMedGoogle Scholar
  81. 81.
    Zyhlarz G, Saletu B, Hitzenberger G, et al. Double-blind, placebo-controlled, pharmacokinetic and dynamic studies with two new formulations of piracetam (infusion and syrup) under hypoxia in man. Neuropsychopharmacology 1994; 10: 117SGoogle Scholar
  82. 82.
    Preda L, Alberoni M, Bressi S, et al. Effects of acute doses of oxiracetam in the scopolamine model of human amnesia. Psychopharmacology 1993; 110: 421–6PubMedGoogle Scholar
  83. 83.
    Saletu B, Schulz H, Herrmann WM, et al. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies. Pharmacopsychiatry 1994; 27: 189–97PubMedGoogle Scholar
  84. 84.
    Saletu B, Grunberger J, Anderer R. On brain protection of codergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 510–24PubMedGoogle Scholar
  85. 85.
    Saletu B, Anderer P, Grunberger J. Topographic brain mapping of EEG after acute application of ergotalkaloids in the elderly. Arch Gerontol Geriatr 1990; 11: 1–22PubMedGoogle Scholar
  86. 86.
    Patat A, Klein MJ, Surjus A, et al. RU 41,656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers. Eur J Clin Pharmacol 1991; 41: 225–31PubMedGoogle Scholar
  87. 87.
    Patat A, Klein MJ, Surjus A, et al. Study of the potential reversal of triazolam memory and cognitive deficits by RU 41 656 in healthy subjects. Psychopharmacol Bed 1991; 104: 75–80Google Scholar
  88. 88.
    Bruins J, Kumar A, Schneider Helmert D. Influence of desglycinamide-(arg8) vasopressin on memory in healthy subjects. Neuropsychobiology 1990; 23: 82–8PubMedGoogle Scholar
  89. 89.
    Bruins J, Hijman R, Van Ree JM. Effect of a single dose of des-glycinamide-[Arg8]vasopressin or oxytocin on cognitive processes in young healthy subjects. Peptides 1992; 13: 461–8PubMedGoogle Scholar
  90. 90.
    Siegfried KR. First clinical impressions with an ACTH analog (HOE 427) in the treatment of Alzheimer’s disease. Ann NY Acad Sci 1991; 640: 280–3PubMedGoogle Scholar
  91. 91.
    Wesnes KA, Simpson PM, White L, et al. HOE-427, a cholinergically active neuropeptide, improves cognitive efficiency in the elderly. Biol Psychiatry 1991; 29: 691Google Scholar
  92. 92.
    Molchan SE, Mellow AM, Lawlor BA, et al. TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 1990; 100: 84–9PubMedGoogle Scholar
  93. 93.
    Glue P, Bailey J, Wilson S, et al. Thyrotropin-releasing hormone selectively reverses lorazepam-induced sedation but not slowing of saccadic eye movements. Life Sci 1992; 50: Pl25–30PubMedGoogle Scholar
  94. 94.
    Wesnes KA, Simpson PM, White L, et al. Cholinesterase inhibition in the scopolamine model of dementia. Ann NY Acad Sci 1991; 640: 268–71PubMedGoogle Scholar
  95. 95.
    Wallnöfer A, Prescott J, Malek N, et al. Physostigmine improves cognitive performance and alters EEG in healthy volunteers — an approach to study central cholinergic effects. Neuropsychopharmacology 1994; 10: 39SGoogle Scholar
  96. 96.
    Wesnes KA, Simpson P, Christmas L, et al. Effects of HP029 in a scopolamine model of ageing and dementia. 17th Congress of C.I.N.P.: 1990 Sep 9–13; Kyoto, 235Google Scholar
  97. 97.
    Lines CR, Ambrose JH, Heald A, et al. A double-blind, placebo controlled study of the effects of eptastigmine on scopolamine-induced cognitive deficits in healthy male subjects. Hum Psychopharmacol 1993; 8: 271–8Google Scholar
  98. 98.
    Brass EP, Polinsky R, Sramek JJ, et al. Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans. J Clin Psychopharmacol 1995; 15: 58–62PubMedGoogle Scholar
  99. 99.
    Rusted J, Eaton-Williams P. Distinguishing between attentional and amnestic effects in information processing: the separate and combined effects of scopolamine and nicotine on verbal free recall. Psychopharmacology 1991; 104: 363–6PubMedGoogle Scholar
  100. 100.
    Hindmarch I, Kerr JS, Sherwood N. Effects of nicotine gum on psychomotor performance in smokers and non-smokers. Psychopharmacology 1990; 100: 535–41PubMedGoogle Scholar
  101. 101.
    Kerr JS, Sherwood N, Hindmarch I. Separate and combined effects of the social drugs on psychomotor performance. Psychopharmacology Berl 1991; 104: 113–9PubMedGoogle Scholar
  102. 102.
    Newhouse PA, Penetar DM, Fertig JB, et al. Stimulant drug effects on performance and behavior after prolonged sleep deprivation: a comparison of amphetamine, nicotine, and deprenyl. Mil Psychol 1992; 4: 207–33Google Scholar
  103. 103.
    Rusted J, Graupner L, O’Connell N, et al. Does nicotine improve cognitive function? Psychopharmacology 1994; 115: 547–9PubMedGoogle Scholar
  104. 104.
    Le Houezec J, Halliday R, Benowitz NL, et al. A low dose of subcutaneous nicotine improves information processing in non-smokers. Psychopharmacology 1994; 114: 628–34PubMedGoogle Scholar
  105. 105.
    Riedel WJ, Hogervorst E, Leboux RLAM, et al. Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 1995; 122: 158–68PubMedGoogle Scholar
  106. 106.
    Soetens E, D’Hooge R, Hueting JE. Amphetamine enhances human-memory consolidation. Neurosci Lett 1993; 161: 9–12PubMedGoogle Scholar
  107. 107.
    Vincent A, Risinger R, Schmidt M, et al. Cognitive effects of idazoxan in normal volunteers. Neuropsychopharmacology 1994; 10: 115SGoogle Scholar
  108. 108.
    Preston GC, Millson DS, Ceuppens PR, et al. Effects of the 5-HT3 receptor antagonist GR68755 on a scopolamine induced cognitive deficit in healthy subjects. Br J Clin Pharmacol 1992; 33: 546Google Scholar
  109. 109.
    Wesnes K, Anand R, Lorscheid T. Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. Acta Psychiatr Scand Suppl 1990; 360: 71–2PubMedGoogle Scholar
  110. 110.
    Curran HV, Birch B. Differentiating the sedative, psychomotor and amnesic effects of benzodiazepines: a study with midazolam and the benzodiazepine antagonist, flumazenil. Psychopharmacol Berl 1991; 103: 519–23Google Scholar
  111. 111.
    Ghoneim MM, Block RI, Ping ST, et al. The interactions of midazolam and flumazenil on human memory and cognition. Anesthesiology 1993; 79: 1183–92PubMedGoogle Scholar
  112. 112.
    Hommer D, Weingartner HJ, Breier A. Dissociation of benzodiazepine-induced amnesia from sedation by flumazenil pretreatment. Psychopharmacology 1993; 112: 455–60PubMedGoogle Scholar
  113. 113.
    Duka T, Edelmann V, Schutt B, et al. Scopolamine-induced amnesia in humans: lack of effects of the benzodiazepine receptor antagonist β-carboline ZK 93426. J Psychopharmacol 1992; 6: 382–8PubMedGoogle Scholar
  114. 114.
    Jones RW, Wesnes KA, Kirby J. Effects of NMDA modulation in scopolamine dementia. Ann NY Acad Sci 1991; 640: 241–4PubMedGoogle Scholar
  115. 115.
    Wesnes K, Jones RW, Kirby J, et al. D-Cycloserine antagonizes scopolamine induced memory impairments and improves memory in the elderly. Biol Psychiatry 1991; 29: 700SGoogle Scholar
  116. 116.
    Wesnes K, Jones RW, Kirby J. The effects of D-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia. Br J Clin Pharmacol 1991; 31: 577–8Google Scholar
  117. 117.
    Camp-Bruno JA, Herting RL, Winsberg BG. Milacemide effects on memory and vigilance. Biol Psychiatry 1991; 29: 286Google Scholar
  118. 118.
    Yu G, Maskray V, Jackson SH, et al. A comparison of the central nervous system effects of caffeine and theophylline in elderly subjects. Br J Clin Pharmacol 1991; 32: 341–5PubMedGoogle Scholar
  119. 119.
    Mattila ME, Mattila MJ, Nuotto E. Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects. Pharmacol Toxicol 1992; 70: 286–9PubMedGoogle Scholar
  120. 120.
    Hasenfratz M, Bunge A, Dal Pra G, et al. Antagonistic effects of caffeine and alcohol on mental performance parameters. Pharmacol Biochem Behav 1993; 46: 463–5PubMedGoogle Scholar
  121. 121.
    Rush CR, Higgins ST, Hughes JR, et al. Acute behavioral effects of triazolam and caffeine, alone and in combination, in humans. Exp Clin Psychopharmacol 1994; 2: 211–22Google Scholar
  122. 122.
    Lorist MM, Snel J, Kok A, et al. Influence of caffeine on selective attention in well rested and fatigued subjects. Psychophysiology 1994; 31: 525–34PubMedGoogle Scholar
  123. 123.
    Lorist MM, Snel J, Kok A. Influence of caffeine on information processing stages in well rested and fatigued subjects. Psychopharmacology 1994; 113: 411–21PubMedGoogle Scholar
  124. 124.
    Tiplady B, Fagan D, Lamont M, et al. A comparison of the CNS effects of enprofylline and theophylline in healthy subjects assessed by performance testing and subjective measures. Br J Clin Pharmacol 1990; 30: 55–61PubMedGoogle Scholar
  125. 125.
    Meador KJ, Nichols ME, Franke P, et al. Evidence for a central cholinergic effect of high-dose thiamine. Ann Neurol 1993; 34: 724–6PubMedGoogle Scholar
  126. 126.
    Benton D, Owens DS. Blood glucose and human memory. Psychopharmacology 1993; 113: 83–8PubMedGoogle Scholar
  127. 127.
    Rosadini G, Sannita WG, Nobili F, et al. Phosphatidylserine: quantitative EEG effects in healthy volunteers. Neuropsychobiology 1990; 24: 42–8PubMedGoogle Scholar
  128. 128.
    Ladd SL, Sommer SA, LaBerge S, et al. Effect of phosphatidylcholine on explicit memory. Clin Neuropharmacol 1993; 16: 540–9PubMedGoogle Scholar
  129. 129.
    Meyer FP. Influence of nifedipine on human performance following a single dose — differential psychopharmacological aspects. Hum Psychopharmacol 1994; 9: 93–100Google Scholar
  130. 130.
    Lines CR, Preston GC, Dawson CE, et al. The effects of pretreatment with enalapril maleate on scopolamine-induced cognitive deficits in healthy volunteers. J Psychopharmacol 1991; 5: 228–33PubMedGoogle Scholar
  131. 131.
    Israel L, Melac M, Milinkevitch D, et al. Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairment. Int Psychogeriatr 1994; 6: 155–70PubMedGoogle Scholar
  132. 132.
    Mauri M, Sinforiani E, Reverberi F, et al. Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers. Arch Gerontol Geriatr 1994; 18: 133–9PubMedGoogle Scholar
  133. 133.
    Dodt C, Pietrowsky R, Sewing A, et al. Effects of vasopressin on event-related potential indicators of cognitive stimulus processing in young and old humans. J Gerontol 1994; 49: M183–8PubMedGoogle Scholar
  134. 134.
    Wang Z-X, Ren Q-Y, Shen Y-C. A Double-blind, control study of huperzine A and piracetam in patients with age-associated memory impairment and Alzheimer’s disease. Neuropsychopharmacology 1994; 10: 763SGoogle Scholar
  135. 135.
    Saletu B, Darragh A, Breuel HP, et al. EEG mapping central effects of multiple doses of linopirine — a cognitive enhancer in healthy elderly male subjects. Hum Psychopharmacol 1991; 6: 267–75Google Scholar
  136. 136.
    McEntee WJ, Crook TH, Jenkyn LR, et al. Treatment of age-associated memory impairment with guanfacine. Psychopharmacol Bull 1991; 27: 41–6PubMedGoogle Scholar
  137. 137.
    Poitrenaud J, Piette F, Malbezin M, et al. Almitrine-raubasine and cognitive impairment in the elderly: results of a 6-month controlled multicenter study. Clin Neuropharmacol 1990; 13: 100–8Google Scholar
  138. 138.
    Wesnes K, Neuman E, De Wilde HJG, et al. Pharmacodynamic effects of repeated oral administration of 4 different doses of S12024-2 (cognitive enhancer) in 36 healthy elderly volunteers. Neurobiol Aging 1994; 15: 100Google Scholar
  139. 139.
    Crook TH, Lakin M. Effects of ondansetron in age-associated memory impairment. Biol Psychiatry 1991; 2: 888–90Google Scholar
  140. 140.
    Searle & Co. Multicenter, randomized, double-blind study of 1 mg, 5 mg and 15 mg b.i.d. of cycloserine vs placebo in the treatment of age-associated memory impairment [technical report]. 1993, EC 6-93-02-007Google Scholar
  141. 141.
    Schwartz BL, Hashtroudi S, Herting RL, et al. Glycine prodrug facilitates memory retrieval in humans. Neurology 1991; 41: 1341–3PubMedGoogle Scholar
  142. 142.
    Benton D, Fordy J, Haller J. The impact of long-term vitamin supplementation on cognitive functioning. Psychopharmacology 1995; 117: 298–305PubMedGoogle Scholar
  143. 143.
    Deijen JB, Van der Beek EJ, Orlebeke JF, et al. Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort. Psychopharmacology 1992; 109: 489–96PubMedGoogle Scholar
  144. 144.
    Hindmarch I, Coleston DM, Kerr JS. Psychopharmacological effects of pyritinol in normal volunteers. Neuropsychobiology 1990; 24: 159–64PubMedGoogle Scholar
  145. 145.
    Kün;kel H. EEG profile of three different extractions of ginkgo biloba. Neuropyschobiology 1993; 27: 40–5Google Scholar
  146. 146.
    Münte TF, Heinze HJ, Matzke M, et al. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27: 46–53PubMedGoogle Scholar
  147. 147.
    Saletu B, Grunberger J, Linzmayer L, et al. EEG brain mapping and psychometry in age-associated memory impairment after acute and 2-week infusions with the hemoderivative actovegin: double-blind, placebo-controlled trials. Neuropsychobiology 1990; 24: 135–48PubMedGoogle Scholar
  148. 148.
    Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology 1991; 41: 644–9PubMedGoogle Scholar
  149. 149.
    Sudilovsky A, Crook T, Repetti S, et al. Angiotensin converting enzyme inhibitors (ACEI) and cognitive functioning in animals and man. Biol Psychiatry 1991; 29: 287Google Scholar
  150. 150.
    Bruce-Jones PN, Crome P, Kalra L. Indomethacin and cognitive function in healthy elderly volunteers. Br J Clin Pharmacol 1994; 38: 45–51PubMedGoogle Scholar
  151. 151.
    Vernon MW, Sorkin EM. Piracetam: an overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1991; 1: 17–35PubMedGoogle Scholar
  152. 152.
    Mondadori C. In search of the mechanism of action of the nootropics: new insights and potential clinical implications. Life Sci 1994; 55: 2171–8PubMedGoogle Scholar
  153. 153.
    Stelmach GE, Zelaznik HN, Lowe D. The influence of aging and attentional demands on recovery from postural instability. Aging 1990; 2: 155–61PubMedGoogle Scholar
  154. 154.
    Teasdale N, Bard C, LaRue J, et al. On the cognitive penetrability of posture control. Exp Aging Res 1993; 19: 1–13PubMedGoogle Scholar
  155. 155.
    Wadworth AN, Chrisp P. Co-dergocrine mesylate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging 1992; 2: 153–73PubMedGoogle Scholar
  156. 156.
    Jolles J. Vasopressin and human behavior. In: Gash DM, Boer GJ, editors. Vasopressin, principles and properties. New York: Plenum Press, 1987: 549–78Google Scholar
  157. 157.
    McEntee WJ, Crook TH. Cholinergic function in the aged brain: implications for treatment of memory impairments associated with aging. Behav Pharmacol 1992; 3: 327–36PubMedGoogle Scholar
  158. 158.
    Bodick NC, DeLong AF, Bonate PL, et al. Xanomeline, a specific Ml agonist: early clinical studies. In: Giacobini E, Becker RE, editors. Alzheimer’s disease: therapeutic strategies. Basel: Birkhäuser Verlag AG, 1994: 234–8Google Scholar
  159. 159.
    Sahakian B, Jones GMM, Levy R, et al. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 1989; 154: 797–800PubMedGoogle Scholar
  160. 160.
    Jones GMM, Sahakian BJ, Levy R, et al. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease. Psychopharmacology 1992; 108: 485–94PubMedGoogle Scholar
  161. 161.
    Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease. Drugs Aging 1994; 4: 510–40PubMedGoogle Scholar
  162. 162.
    Giacobini E, Becker R. Development of drugs for Alzheimer therapy: a decade of progress. In: Giacobini E, Becker RE, editor. Alzheimer’s disease: therapeutic strategies. Basel: Birkhäuser Verlag AG, 1994: 1–7Google Scholar
  163. 163.
    Van Duijn M, Hofman A. Relation between nicotine intake and Alzheimer’s disease. BMJ 1991; 302: 1491–4PubMedGoogle Scholar
  164. 164.
    Newhouse PA, Potter A, Corwin J, et al. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacol Berl 1992; 108: 480–4Google Scholar
  165. 165.
    Newhouse PA, Potter A, Corwin J, et al. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 1994; 10: 93–107PubMedGoogle Scholar
  166. 166.
    McGehee D, Heath M, Gelber S, et al. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995; 269: 1692–6PubMedGoogle Scholar
  167. 167.
    Coull JT. Pharmacological manipulations of the α2-noradrenergic system: effects on cognition. Drugs Aging 1994; 5: 116–26PubMedGoogle Scholar
  168. 168.
    Robbins T, Everitt B. Arousal systems and attention. In: Gazzangia M, editor. The cognitive neurosciences. Cambridge (MA): MIT Press, 1995: 703–20Google Scholar
  169. 169.
    McEntee WJ, Crook TH. Serotonin, memory, and the aging brain. Psychopharmacol Berl 1991; 103: 143–9Google Scholar
  170. 170.
    Porsolt RD. Serotonin: neurotransmitter ‘a la mode’. Report on the Third International I.T.E.M.–LABO symposium on strategies in psychopharmacology. Serotonin: animal models and clinical targets. Pharmacopsychiatry 1993; 26: 20–4PubMedGoogle Scholar
  171. 171.
    Muller T, Kuhn W, Przuntek H. Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J Neural Transm Gen Sect 1993; 92: 187–95PubMedGoogle Scholar
  172. 172.
    Stoll S, Hafner U, Pohl O, et al. Age-related memory decline and longevity under treatment with selegiline. Life Sci 1994; 55: 2155–63PubMedGoogle Scholar
  173. 173.
    Houx PJ, Vreeling FW, Jolles J. Stroop interference: aging effects assessed with the Stroop Color-Word Test. Exp Aging Res 1993; 19: 209–24PubMedGoogle Scholar
  174. 174.
    Tariot PN, Cohen RM, Sunderland T, et al. L-Deprenyl in Alzheimer’s disease. Arch Gen Psychiatry 1987; 44: 427–33PubMedGoogle Scholar
  175. 175.
    Schneider LS, Tariot PN, Goldstein B. Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther 1994; 56: 750–6PubMedGoogle Scholar
  176. 176.
    Ziegler G, Ludwig L, Fritz G. Effect of the specific benzodiazepine antagonist Ro 15-1788 on sleep. Pharmacopsychiatry 1986; 19: 200–1Google Scholar
  177. 177.
    O’Hanlon JF, Vermeeren A. Effects of Ro 15-1788 on the vigilance performance of sleep-deprived men. Hum Psychopharmacol 1988; 3: 267–74Google Scholar
  178. 178.
    Herting RL. Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia. Ann NY Acad Sci 1991; 640: 237–40PubMedGoogle Scholar
  179. 179.
    Müller WE, Scheuer K, Stoll S. Glutamatergic treatment strategies for age-related memory disorders. Life Sci 1994; 55: 2147–53PubMedGoogle Scholar
  180. 180.
    Markowitsch H. Intellectual functions and the brain. An historical perspective. Seattle: Hogrefe and Huber, 1992Google Scholar
  181. 181.
    Lieberman HR, Wurtman RJ, Emde GG, et al. The effects of low doses of caffeine on human performance and mood. Psychopharmacology 1987; 92: 308–12PubMedGoogle Scholar
  182. 182.
    Biaggioni I, Subir P, Puckett A, et al. Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 1991; 258: 588–93PubMedGoogle Scholar
  183. 183.
    Swift CG, Tiplady B. The effects of age on the response to caffeine. Psychopharmacology 1988; 94: 29–31PubMedGoogle Scholar
  184. 184.
    Stavric B. An update on research with coffee/caffeine (1989-1990). Food Chem Toxicol 1992; 30: 533–5PubMedGoogle Scholar
  185. 185.
    Nehlig A, Daval J-L, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 1992; 17: 139–70PubMedGoogle Scholar
  186. 186.
    Briley M. Biochemical strategies in the search for cognition enhancers. Pharmacopsychiatry 1990; 2: 75–80Google Scholar
  187. 187.
    Jarvis M. Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology 1993; 110: 45–52PubMedGoogle Scholar
  188. 188.
    Benton D. Vitamin-mineral supplements and intelligence. Proc Nutr Soc 1992; 51: 295–302PubMedGoogle Scholar
  189. 189.
    Bohnen N, Jolles J, Degenaar CP. Lower blood levels of vitamin B12 are related to decreased performance of healthy subjects in the Stroop Color Word Test. Neurosci Res Commun 1992; 11: 53–6Google Scholar
  190. 190.
    Loriaux SM, Deijen JB, Orlebeke JF, et al. The effects of nicotinic acid and xanthinol nicotate on human memory in different categories of age. Psychopharmacology 1985; 87: 390–5PubMedGoogle Scholar
  191. 191.
    Kleijnen J, Knipschild P. Niacin and vitamin B6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry 1991; 29: 931–41PubMedGoogle Scholar
  192. 192.
    Micheau J, Durkin TP, Destrade C, et al. Chronic administration of sulbutiamine improves long term memory formation in mice: possible cholinergic mediation. Pharmacol Biochem Behav 1985; 23: 195–8PubMedGoogle Scholar
  193. 193.
    Consolis S, Mas M. Intérêt d’un antiasthénique polyvalent, Arcalion 200 sur la vigilance et le stress des sportifs en haute compétition [in French]. Psychol Med 1988; 20: 2Google Scholar
  194. 194.
    Israel L, Dell’Acio E, Hugonot R. Arcalion 200 entraînement mental. Intérêts d’Arcalion 200 chez les personnes âgées asthéniques. Journale de Médecine Pratique 1989; Suppl. 1: 19–24Google Scholar
  195. 195.
    Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992; 34: 352–8PubMedGoogle Scholar
  196. 196.
    Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992; 340: 1136–9PubMedGoogle Scholar
  197. 197.
    Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993; 43: 1609–11PubMedGoogle Scholar
  198. 198.
    Semlitsch HV, Anderer P, Saletu B, et al. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment. Neuropsychobiology 1990; 24: 49–56PubMedGoogle Scholar
  199. 199.
    O’Brien AJ, Bulpitt CJ. The effects of ACE inhibitors on cognitive function. Drugs Aging 1995; 6: 173–80PubMedGoogle Scholar
  200. 200.
    Wenk GL. An hypothesis on the role of glucose in the mechanism of action of cognitive enhancers. Psychopharmacology 1989; 99: 431–8PubMedGoogle Scholar
  201. 201.
    Benton D, Sargent J. Breakfast, blood glucose and memory. Biol Psychol 1992; 33: 207–10PubMedGoogle Scholar
  202. 202.
    Guez D, Malbezin M, Neuman E, et al. S12024, a new drug in development for the treatment of Alzheimer’s disease. Update on dementia and functional disorders in old age; 1994 Jul 13–14: LondonGoogle Scholar
  203. 203.
    Houx PJ, Vreeling FW, Jolies J. Rigorous health screening reduces age effect on memory scanning task. Brain Cogn 1991; 15: 246–60PubMedGoogle Scholar
  204. 204.
    Bohnen NI, Twijnstra A, Jolies J. A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma. Neurology 1993; 43: 103–6PubMedGoogle Scholar
  205. 205.
    Saletu B, Saletu M, Grünberger J, et al. Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neuropsychobiology 1993; 27: 26–39PubMedGoogle Scholar
  206. 206.
    Aldenkamp AP, Wieringen Av, Alpherts WCJ, et al. Doubleblind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy. Neuropsychobiology 1990; 24: 90–101PubMedGoogle Scholar
  207. 207.
    Somnier FE, Ostergaard MS, Boysen G, et al. Aniracetam tested in chronic psychosyndrome after long-term exposure to organic solvents. A randomized, double-blind, placebo-controlled cross-over study with neuropsychological tests. Psychopharmacology 1990; 101: 43–6PubMedGoogle Scholar
  208. 208.
    Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendo crinology 1992; 17: 485–95Google Scholar
  209. 209.
    Gaillard A. The evaluation of drug effects in laboratory tasks. In: Hindmarch I, Aufdembrinke B, Ott H, editors. Psychopharmacology and reaction time. Chichester: John Wiley &Sons, 1988: 15–24Google Scholar
  210. 210.
    Riedel WJ, Hamers HMW, Robbe HWJ, et al. Automated behavioral testing in psychotropic drug research. In: Mulder LJM, Maarse FJ, Sjouw WPB, et al., editors. Computers in psychology: applications in education, research and psychodiagnostics. Amsterdam: Swets & Zeitlinger, 1991: 166–70Google Scholar
  211. 211.
    Larrabee GJ, Crook T. A computerized everyday memory battery for assessing treatment effects. Psychopharmacol Bull 1988; 24: 695–7PubMedGoogle Scholar
  212. 212.
    Simpson PM, Surmon DJ, Wesnes KA, et al. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991; 6: 95–102Google Scholar
  213. 213.
    Jolies J. Aging of brain & behavior: biomedical, clinical and behavioral research in the domain of aging at the University of Limburg. In: Van Bezooijen CFA, Ravid R, Verhofstad AAJ, editors. From gene to man. The Hague: J.H. Pasmans Publishers, 1990: 146–50Google Scholar
  214. 214.
    Rusted J. Cholinergic blockade and human information processing: are we asking the right questions? J Psychopharmacol 1994; 8: 54–9PubMedGoogle Scholar
  215. 215.
    Salin PR, Granados FD, Galicia PL, et al. Development of tolerance after repeated administration of a selective muscarinic M1 antagonist biperiden in healthy human volunteers. Biol Psychiatry 1993; 33: 188–93Google Scholar
  216. 216.
    File SE, Goodall EM, Mabbutt PS, et al. State-dependent retrieval and midazolam. Hum Psychopharm 1993; 8: 243–51Google Scholar
  217. 217.
    Birch B, Curran HV. The differential effects of flumazenil on the psychomotor and amnesic actions for midazolam. J Psychopharmacol 1990; 4: 29–34PubMedGoogle Scholar
  218. 218.
    Rother M, Kessler J, Funke M, et al. Memory impairment after hyperventilation-a physiological model of cognitive dysfunctions. Neurobiol Aging 1994; 15: 92Google Scholar
  219. 219.
    Stoppe G, Sandholzer H, Staedt J, et al. Reasons for prescribing cognition enhancers in primary care: results of a representative survey in Lower Saxony, Germany. Int J Clin Pharmacol Ther 1995; 33: 486–90PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  1. 1.Maastricht Brain and Behaviour Institute, Department of Psychiatry and NeuropsychologyUniversity of LimburgMaastrichtThe Netherlands

Personalised recommendations